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Executive summary
• Post-acute coronavirus disease-19 (COVID-19) respiratory 
symptoms are common and may be caused by a variety of factors 
including, among others, cardiac and respiratory dysfunction.
• A detailed history and examination with appropriate investigations 
is imperative to define the exact nature of the dysfunction.
• Limited data exist to guide evidence-based approaches to treatment.
• Injudicious use of corticosteroids is cautioned against as well as 
indiscriminate use of off-label drugs.
Background and nomenclature
The COVID-19 pandemic caused by the severe acute respiratory 
syndrome-coronavirus-2 (SARS-CoV-2) has caused significant 
mortality and morbidity in South Africa. The initial clinical focus 
was on the waves of acute disease and the focus has now shifted 
to those with post-COVID-19 symptoms and impairments. It is 
anticipated that COVID-19 will have a long-term impact on the 
physical, emotional, mental, cognitive, and social status of survivors.
Most patients have mild COVID-19, while a minority of those with 
acute symptoms require hospitalisation (~10 - 15% depending on age 
and comorbidities), and only a fraction of these require intensive care 
support (~3 - 5% of those hospitalised). COVID-19 is responsible 
for considerable mortality in hospitalised patients, and those that 
survive may have significant ongoing health issues after discharge.[1-4] 
It is also now well recognised that many patients who did not require 
hospitalisation or intensive care support, may also have ongoing 
symptoms for weeks or months after the acute illness.[1-4] 
The spectrum of pulmonary involvement in COVID-19 is extensive, 
and the clinical and radiological presentation of severe COVID-19 
pneumonia is variable. It is not yet known to what extent acute 
infection results in long term respiratory impairments nor the time 
course to potential resolution.[5-7] These are often referred to as 
post-COVID-19 lung disease, long-COVID, or COVID-19 pulmonary 
fibrosis/ post-COVID-19 organising pneumonia. More recently, the 
term post-acute sequelae of SARS-CoV-2 infection (PASC) has been 
used as an umbrella term to collectively describe these effects. 
There are currently no clinical trials to provide high-quality data 
to guide the clinical care of this growing patient population[8]. The 
South African Thoracic Society position statement on post-COVID 
lung disease is to assist clinicians in managing patients with persistent 
respiratory symptoms following proven or suspected COVID-19.
Recommendations
We recommend the following:
1.  Patients who required intensive care or ventilatory support 
(including high flow nasal oxygen) may have residual respiratory 
symptoms and deficits.[5,7] Follow-up with a specialist physician 
or pulmonologist is advised.
2.  Post-acute respiratory distress syndrome pulmonary fibrosis is 
a well-recognised condition and responds poorly to available 
medical therapies.[9] Follow-up with a specialist physician or 
pulmonologist is advised. 
3.  Organising pneumonia is a clinical entity usually diagnosed on 
histology, together with compatible radiology, and upon the 
exclusion of an ongoing infectious process. This condition generally 
responds well to oral corticosteroids but is diagnosed by exclusion 
and should not be made using radiology alone.[10,11] Patients with 
radiological features of organising pneumonia should be referred 
to a pulmonologist for further investigation, multidisciplinary team 
discussion, and consideration of therapeutic interventions. 
4.  SARS-CoV-2 infection may result in prolonged cardiovascular, 
neurocognitive, and psychiatric problems. Patients with persistent 
symptoms (>3 months) should be referred to the appropriate 
specialist for further investigation.[12] 
5.  Fatigue is a common symptom following both mild and severe 
COVID-19 and may be multifactorial in aetiology. Patients with 
persistent fatigue (>3 months) should be investigated broadly before 
attributing fatigue to respiratory deficits.[12,13] A referral to a specialist 
physician is advised. 
6.  There are no proven therapies for post-COVID-19 lung disease. 
Referral of patients to specialist units or to units undertaking clinical 
trials is advised. The use of experimental/unproven therapies should 
only be considered by specialist respiratory units, those doing clinical 
trials, or multidisciplinary teams. 
7.  Evidence for the use of corticosteroids is limited but their use may 
be appropriate in a subset of patients with persistent, non-improving 
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symptoms, in the presence of a multidisciplinary team-confirmed 
interstitial lung disease and objective impairment in lung 
function.[14] 
8.  Clinical details should be comprehensively recorded, decision-
making should be rational and carefully documented, and patients 
should be closely monitored. The injudicious use of high-dose 
prolonged courses of corticosteroids, immunomodulatory drugs 
such as azithromycin, or antifibrotic agents such as pirfenidone, 
is discouraged. 
Workup
Suggestions for initial workup:
1.  A detailed history of pre-COVID-19 clinical status, comorbidities, 
effort tolerance, functional status, in addition to medication and 
smoking history should be ascertained. 
2.  A SARS-CoV-2 PCR should ideally be performed and confirmed 
to be negative prior to physiological testing (lung function/6-
minute walk/exercise test etc.) in accordance with infection 
prevention and control policies and guidelines. Patients may 
have persistent positive PCR of uncertain significance and while 
ongoing infectiousness is unlikely, staff/patient safety must be 
prioritised[15]. 
3.  Stress-testing, sub-maximal exercise testing, and maximal exercise 
testing should be used with caution within 3 months of the acute 
illness due to the risk of exacerbating fatigue, myositis, and 
myocarditis. 
4.  A thorough clinical and laboratory evaluation should be performed 
for common causes of fatigue, including an evaluation of sleep 
and mental health changes, haemoglobin, thyroid function, renal 
function, creatinine kinase, and glycated haemoglobin A1C.[1,16]
5.  An electrocardiogram, spirometry, pulse oximetry and chest 
radiograph are recommended for the initial investigation of 
persistent respiratory or cardiovascular symptoms.[12-14]
6.  Specialised investigation with high resolution computerised 
tomography (CT), CT pulmonary angiography, echocardiography, 
coronary angiography, and neurocognitive studies should be 
considered for patients with persistent symptoms (>3 months) 
who are not on an improving clinical trajectory, or in whom 
initial testing (as above) warrants further specialist investigation. 
Bronchoscopy with lavage and biopsies should also be considered 
where indicated.[10,11,17]
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